| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
ZEN-3862 targets the bromodomain and extra-terminal (BET) family of proteins, specifically the BRD4 bromodomains BD1 and BD2. BET proteins are epigenetic readers that recognize acetylated lysine residues on histone tails and play critical roles in transcriptional regulation. ZEN-3862 inhibits BRD4 with IC50 values of 0.16 microM for the BD1 domain and 0.13 microM for the BD2 domain. By disrupting the interaction between BET proteins and acetylated histones, ZEN-3862 modulates gene expression programs involved in cancer and other diseases.
|
|---|---|
| ln Vitro |
In vitro, ZEN-3862 demonstrates potent inhibition of BET proteins with IC50 values of 0.16 microM for BRD4(BD1) and 0.13 microM for BRD4(BD2). The compound effectively disrupts protein-protein interactions critical for transcriptional regulation, leading to modulation of gene expression. ZEN-3862 can be used to form PROTACs (proteolysis-targeting chimeras) to induce selective degradation of BRD4, offering a complementary approach to target BET proteins beyond simple enzymatic inhibition. The compound has a purity of ≥95-98%.
|
| ln Vivo |
Detailed in vivo activity data for ZEN-3862 are not extensively documented in publicly available literature. As a BET inhibitor, ZEN-3862 is expected to exhibit antitumor activity in various cancer models by modulating the expression of oncogenes such as MYC. The compound's utility as a ligand in PROTAC design suggests potential applications in targeted protein degradation strategies for in vivo therapeutic development. ZEN-3862 is soluble in DMSO at 83.33 mg/mL (244.84 mM), facilitating formulation for in vivo administration.
|
| Enzyme Assay |
Receptor binding or enzyme activity assays for ZEN-3862 are performed using purified recombinant BRD4 bromodomains (BD1 and BD2). Binding affinity is measured using methods such as AlphaScreen, fluorescence polarization, or surface plasmon resonance (SPR). ZEN-3862 is incubated with the BRD4 bromodomain and a labeled acetylated histone peptide at varying concentrations. The displacement of the labeled ligand is measured to determine IC50 values. Nonspecific binding is determined in control reactions without the compound or with excess unlabeled competitor.
|
| Cell Assay |
Cellular assays for ZEN-3862 are performed using cancer cell lines that are sensitive to BET inhibition. Cells are cultured in appropriate media and treated with ZEN-3862 at varying concentrations for defined time periods. The effects on cell viability and proliferation are assessed using standard assays such as MTT, CellTiter-Glo, or colony formation assays. Changes in the expression of BET-regulated genes such as MYC are measured by qRT-PCR or Western blot. For PROTAC applications, cells are treated with ZEN-3862-based PROTACs and target protein degradation is assessed by Western blot analysis.
|
| Animal Protocol |
In vivo studies with ZEN-3862 are conducted in mouse xenograft models using cancer cell lines sensitive to BET inhibition. The compound is administered via appropriate routes (e.g., oral, intraperitoneal, or intravenous) at defined doses and schedules. Tumor growth is monitored by caliper measurements, and tumor volumes are calculated. For PROTAC applications, ZEN-3862-based PROTACs are evaluated for their ability to degrade BRD4 in tumor tissues, as assessed by Western blot or immunohistochemistry. The compound is soluble in DMSO at 83.33 mg/mL for formulation.
|
| ADME/Pharmacokinetics |
ZEN-3862 has a molecular weight of 340.35 and a molecular formula of C19H17FN2O3. The compound is soluble in DMSO at 83.33 mg/mL (244.84 mM). As a small molecule BET inhibitor, ZEN-3862 is expected to have favorable oral bioavailability, although detailed pharmacokinetic parameters are not extensively documented in publicly available literature. The compound is stable when stored at -20degC for up to 2 years.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for ZEN-3862 are not extensively documented in publicly available sources. The compound is intended for research use only and is not approved for human therapeutic applications. Standard laboratory safety practices should be followed when handling this compound, including the use of appropriate personal protective equipment and adherence to institutional biosafety and chemical hygiene guidelines. The compound has a purity of ≥95-98% and is supplied for research purposes.
|
| Additional Infomation |
ZEN-3862 is a potent BET inhibitor with IC50 values of 0.16 microM for BRD4(BD1) and 0.13 microM for BRD4(BD2). It serves as a versatile chemical tool for studying epigenetic modulation and transcriptional control mechanisms. Additionally, ZEN-3862 can be utilized as a ligand in PROTAC design to induce selective degradation of BRD4, offering potential therapeutic applications in cancer and other diseases driven by aberrant BET protein activity. The compound is for research purposes only and is not approved for clinical use.
|
| Molecular Formula |
C19H17FN2O3
|
|---|---|
| Molecular Weight |
340.35
|
| Exact Mass |
340.122
|
| CAS # |
1952264-33-3
|
| PubChem CID |
121414853
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
593
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C(=NO1)C)C2=CN(C(=O)C=C2)CC3=CC(=C(C=C3)C4CO4)F
|
| InChi Key |
VQHDSZCBMWYGEK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H17FN2O3/c1-11-19(12(2)25-21-11)14-4-6-18(23)22(9-14)8-13-3-5-15(16(20)7-13)17-10-24-17/h3-7,9,17H,8,10H2,1-2H3
|
| Chemical Name |
5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[3-fluoro-4-(oxiran-2-yl)phenyl]methyl]pyridin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~244.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9382 mL | 14.6908 mL | 29.3815 mL | |
| 5 mM | 0.5876 mL | 2.9382 mL | 5.8763 mL | |
| 10 mM | 0.2938 mL | 1.4691 mL | 2.9382 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
